Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-04-25 DOI:10.1080/13543784.2024.2347302

Cheng Sun, Hao Liu, Ziwei Ouyang, Jie Ding, Qin Zhang, Hongjie Ma, Dandan Xu, Qian Zhang, Renpeng Zhou, Mingming Yang, Wei Hu

引用次数: 0

Abstract

SHEN26, an oral broad-spectrum antiviral drug, possesses potent preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has a favorable safety profile.We repor...

查看原文本刊更多论文

新型 RdRp 抑制剂 SHEN26 对抗 SARS-CoV-2 的安全性、耐受性和药代动力学：一项针对健康受试者的随机、安慰剂对照、双盲 I 期研究

SHEN26是一种口服广谱抗病毒药物，对严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）具有很强的临床前活性，并具有良好的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.